

Peter Canning, PhD



Dr. Canning obtained a B.Sc. in Microbiology and his PhD in Immunobiology from Iowa State University. He has worked in the animal health research field for the last 30 years holding positions of increasing responsibility in both the federal government and pharmaceutical industry. During his tenure at the USDA, Agricultural Research Service Dr. Canning led Brucellosis research at the National Animal Disease Center defining how the *Brucella* evades destruction by bovine phagocytic cells. Dr. Canning began his pharmaceutical research career at Pfizer Animal Health in Discovery Research where he played a key role in the discovery and early development of novel antibiotics for cattle and swine diseases. After joining Intervet, he established their US drug safety evaluation program and oversaw the assessment of target animal safety profiles for livestock and companion animal pharmaceutical products. Dr. Canning joined Elanco Animal Health in 2004, leading their Technology Acquisition and Biology Research functions. He currently leads the Bioproduct Innovation program focused on discovery of novel biopharmaceuticals for veterinary diseases. Dr. Canning is a co-inventor or development lead for four globally licensed veterinary pharmaceuticals for food producing animals including Imrestor™, an immune restorative agent for preventing clinical mastitis in periparturient cows and heifers.

Contact Information:

Peter C. Canning, PhD
Senior Research Advisor
Bioproduct Innovation
Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140
e-mail: canningpc@elanco.com